Physician profile
Charles Mcdaniel
NPI 1497250377
$2,409.85
in general payments reported to CMS, 2019-2025
18 companies · $1,582 in 2025
The $1,582 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.49 · 2023: $181 · 2024: $628 · 2025: $1,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,359 · Education: $31.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,359.36 |
| Education | $31.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $848.80 | 2024-2025 | |
| Janssen Biotech, INC. | $364.29 | 2024-2025 | Tremfya, Stelara |
| Boston Scientific Corporation | $200.04 | 2022-2023 | |
| Pfizer INC. | $142.77 | 2024-2025 | |
| Madrigal Pharmaceuticals | $138.99 | 2025 | Rezdiffra |
| Ardelyx, INC. | $137.18 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $130.12 | 2024-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $81.12 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $77.90 | 2025 | Voquezna |
| Medtronic, INC. | $68.15 | 2025 | Pillcam |
| Ironwood Pharmaceuticals, INC | $42.75 | 2024 | |
| Intercept Pharmaceuticals, INC. | $41.66 | 2024-2025 | |
| Braintree Laboratories, INC. | $29.80 | 2024-2025 | Sutab, Suflave |
| Regeneron Healthcare Solutions, INC. | $26.54 | 2025 | Dupixent |
| Lilly USA, LLC | $23.69 | 2025 | Omvoh |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $22.95 | 2024 | Rebyota |
| Aimmune Therapeutics, INC. | $18.21 | 2025 | Vowst |
| Ipsen Biopharmaceuticals, INC | $14.89 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.